Berenberg initiated coverage of Haleon with a Buy rating and 407 GBp price target. The analyst says the company’s U.S. launch of Eroxon should drive better than expected organic sales growth of 5.8% in 2025. Haleon’s exposure to attractive categories should allow it to grow by 4.6% in the medium term, which is above the sector average of 4.1%, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HLN:
- Yellow Wood’s Suave completes acquisition of ChapStick from Haleon
- Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition
- GSK announces intention to sell about 385M shares in Haleon
- Haleon plc Shareholders Approve AGM Resolutions
- Haleon Updates £10B EMTN Programme Prospectus